October 24th 2024
Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.
OUtMATCH: Omalizumab Proves Utility in Multiple Food Allergies for Pediatric, Adult Patients
February 25th 2024Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.
FDA Approves Omalizumab as First Treatment of 1 or More Food Allergies for Children, Adults
The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.
FDA Priority Review Granted to Omalizumab for Adults, Children with Food Allergy
The decision by the FDA is a step closer to omalizumab’s potential approval, making it the potential first medicine to reduce reactions to many different food allergens after accidental exposure.
Maternal Egg Consumption During Neonatal Period Ineffective in Preventing Egg Allergy
New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.
Oral Immunotherapy Shown to Be Effective in Desensitization for Egg, Milk, Peanut Allergy
New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.
Black, Asian, Hispanic Populations Have Higher Food Allergy Burden Compared to Non-Hispanic Whites
Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.
Epicutaneous Immunotherapy in Children Aged 1 to 3 Effective for Peanut Allergy Desensitization
This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.